BioVersys plans a Q1 2025 IPO on the SIX Swiss Exchange to raise 80 million francs for Phase III trials of BV100 targeting CRAB and Phase II development of alpibectir for TB meningitis. The company ...

Curreen Capital Partners LP returned 5.71% for Q4 2024 and 7.72% for the year. Click here to read the full fund letter.

Increasing pay for care workers of those with developmental disabilities can save the state money. Among Washington state’s most vulnerable people are some 4,600 who live with significant intellectual ...